Aarti Drugs

AARTI Drugs Q1 FY24 Result Update:
Future Outlook:

• The company expects to achieve a topline growth of ~10% in FY24, primarily backed by volumes.
• It would target to achieve an EBITDA margin of ~14.5%-15% in FY24 and the same is expected to improve further in FY25 with the commissioning of additional capacities.
• Most of the API players reported a volume uptick, backed by improved demand and stable realisations. Keeping this in view, we expect demand for API to continue in the upcoming quarters easing supply chain bottlenecks. We believe that Aarti Drugs, being a leader in the domestic industry, is well-placed to capitalize on prevalent as well as future growth opportunities.